Legal Opinion
Eli Lilly & Co. v. Medtronic, Inc.
Supreme Court of the United States
Decided August 13, 1990No. 89-243PublishedCited by 243 opinions
1Opinion of the CourtJustice Scalia
This case presents the question whether 35 U. S. C. § 271(e)(1) (1982 ed., Supp II) renders activities that would otherwise constitute patent infringement noninfringing if they are undertaken for the purpose of developing and submitting to the Food and Drug Administration (FDA) information necessary to obtain marketing approval for a medical *664device under § 515 of the Federal Food, Drug, and Cosmetic Act (FDCA), 90 Stat. 552, 21 U. S. C. § 360e.
I
In 1983, pursuant to 28 U. S. C. § 1338(a), the predecessor-in-interest of petitioner Eli Lilly & Co. filed an action against respondent Medtronic,…
2Cases cited4 opinions
- Pittston Coal Group v. SebbenSupreme Court of the United States · 1988
- Roche Products, Inc. v. Bolar Pharmaceutical Co., Inc.Court of Appeals for the Federal Circuit · 1984
- Eli Lilly and Company v. Medtronic, Inc.Court of Appeals for the Federal Circuit · 1989
- Fisons Plc v. Donald J. Quigg, Commissioner of Patents & TrademarksCourt of Appeals for the Federal Circuit · 1989
3Cited by243 opinions
- Joy Technologies, Inc., and A/s Niro Atomizer, Involuntary v. Flakt, Inc.Court of Appeals for the Federal Circuit · 1993
- F.T.C. v. Actavis, Inc.Supreme Court of the United States · 2013
- Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/sSupreme Court of the United States · 2012
- Glaxo, Inc., and Glaxo Group Limited v. Novopharm, Ltd.Court of Appeals for the Federal Circuit · 1997
- AstraZeneca AB v. United Food & Commercial Workers UnionsCourt of Appeals for the First Circuit · 2015
238 more not listed; retrieve them via the Exa API.